Therapeutic Targeting of the GSK3 beta-CUGBP1 Pathway in Myotonic Dystrophy

Myotonic Dystrophy type 1 (DM1) is a neuromuscular disease associated with toxic RNA containing expanded CUG repeats. The developing therapeutic approaches to DM1 target mutant RNA or correct early toxic events downstream of the mutant RNA. We have previously described the benefits of the correction of the GSK3 beta-CUGBP1 pathway in DM1 mice (HSA(LR) model) expressing 250 CUG repeats using the GSK3 inhibitor tideglusib (TG). Here, we show that TG treatments corrected the expression of similar to 17% of genes misregulated in DM1 mice, including genes involved in cell transport, development and differentiation. The expression of chloride channel 1 (Clcn1), the key trigger of myotonia in DM1, was also corrected by TG. We found that correction of the GSK3 beta-CUGBP1 pathway in mice expressing long CUG repeats (DMSXL model) is beneficial not only at the prenatal and postnatal stages, but also during adulthood. Using a mouse model with dysregulated CUGBP1, which mimics alterations in DM1, we showed that the dysregulated CUGBP1 contributes to the toxicity of expanded CUG repeats by changing gene expression and causing CNS abnormalities. These data show the critical role of the GSK3 beta-CUGBP1 pathway in DM1 muscle and in CNS pathologies, suggesting the benefits of GSK3 inhibitors in patients with different forms of DM1.

Automated summary

Myotonic Dystrophy type 1 (DM1) is a neuromuscular disease caused by toxic RNA with expanded CUG repeats. Correction of the GSK3 beta-CUGBP1 pathway using the GSK3 inhibitor tideglusib (TG) has shown benefits in DM1 mice. TG treatments corrected the expression of genes involved in cell transport, development, and differentiation, as well as the key trigger of myotonia in DM1. Dysregulated CUGBP1 contributes to the toxicity of expanded CUG repeats and affects gene expression and CNS abnormalities.